Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
-
Revolution Medicines announces $1 billion in proposed stock and note offerings
-
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
-
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
-
TD Cowen: 'Revolution (RVMD) Is Our 2026 Best Idea'
-
Revolution Medicines to Participate in March 2025 Investor Conferences
-
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Revolution Medicines (RVMD) Prices Upsized 14.13M Share Offering at $46/sh
-
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
-
Revolution Medicines (RVMD) Announces Commencement of Public Offering of Common Stock
-
Revolution Medicines Announces Commencement of Public Offering of Common Stock
-
TD Cowen Reiterates Buy Rating on Revolution (RVMD)
-
TD Cowen Reiterates Buy Rating on Revolution (RVMD)
-
TD Cowen Reiterates Buy Rating on Revolution (RVMD)
-
Revolution Medicines to Participate in Upcoming Investor Conferences
-
Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
-
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Revolution Medicines (RVMD) Prices 13.64M Share Offering at $22/sh
-
Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
-
Revolution Medicines (RVMD) Commences Up to $300M Share Offering
-
Revolution Medicines Announces Commencement of Public Offering of Common Stock
-
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Revolution Medicines (RVMD) Prices 11.M Share Offering at $20/sh
-
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
-
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
-
Revolution Medicines (RVMD) Announces Commencement of $200M Public Offering of Common Stock
-
Revolution Medicines Announces Commencement of Public Offering of Common Stock
-
Revolution Medicines Announces Commencement of Public Offering of Common Stock
-
Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors
-
Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
-
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
-
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
-
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
-
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
-
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Revolution Medicines (RVMD) Prices 5.8M Share Common Offering at $45/Sh
-
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
-
Revolution Medicines (RVMD) to Offer 4M Shares of Common Stock
-
Revolution Medicines Announces Proposed Public Offering of Common Stock
-
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress
-
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress
-
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Revolution Medicines (RVMD) Prices 6M Share Common Offering at $36/Sh
-
Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock
-
Revolution Medicines (RVMD) Announces 5.5M Share Proposed Public Offering of Common Stock
-
Revolution Medicines Announces Proposed Public Offering of Common Stock
-
Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors
-
Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors
-
Cowen Starts Revolution (RVMD) at Outperform

